Fremanezumab in the treatment of migraines: evidence to date

Jennifer Robblee, Juliana VanderPluymDepartment of Neurology, Mayo Clinic, Scottsdale, AZ, USACorrespondence: Juliana VanderPluymDepartment of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USAEmail vanderpluym.juliana@mayo.eduAbstract: Calcitonin gene-related peptide (CGRP) is a m...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Journal of Pain Research
المؤلفون الرئيسيون:	Robblee J, VanderPluym J
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Dove Medical Press 2019-08-01
الموضوعات:	fremanezumab migraine headache calcitonin gene-related peptide (CGRP) treatment monoclonal antibody
الوصول للمادة أونلاين:	https://www.dovepress.com/fremanezumab-in-the-treatment-of-migraines-evidence-to-date-peer-reviewed-article-JPR

مواد مشابهة

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
حسب: Ivan Urits, وآخرون
منشور في: (2020-03-01)

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine
حسب: G. N. Belskaya, وآخرون
منشور في: (2024-02-01)

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
حسب: A.Y. Timokhovich, وآخرون
منشور في: (2024-10-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
حسب: Root S, وآخرون
منشور في: (2023-02-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
حسب: Davor Jančuljak, وآخرون
منشور في: (2024-01-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
حسب: Kenta Kashiwagi, وآخرون
منشور في: (2023-02-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
حسب: Suruchi Aditya, وآخرون
منشور في: (2023-01-01)

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab
حسب: Nicola Benedicter, وآخرون
منشور في: (2024-03-01)

A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months
حسب: Shiho Suzuki, وآخرون
منشور في: (2025-06-01)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
حسب: Saigoh K, وآخرون
منشور في: (2023-05-01)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
حسب: Saigoh K, وآخرون
منشور في: (2023-04-01)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
حسب: Piero Barbanti, وآخرون
منشور في: (2022-04-01)

The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
حسب: Mária Dux, وآخرون
منشور في: (2022-05-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
حسب: Anna V. Berdnikova, وآخرون
منشور في: (2023-10-01)

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
حسب: Piero Barbanti, وآخرون
منشور في: (2023-03-01)

Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
حسب: Máté Héja, وآخرون
منشور في: (2025-04-01)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
حسب: Shiho Suzuki, وآخرون
منشور في: (2023-07-01)

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study
حسب: Faisal Mohammad Amin, وآخرون
منشور في: (2025-07-01)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
حسب: Michael Lowe, وآخرون
منشور في: (2022-07-01)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
حسب: Noboru Imai, وآخرون
منشور في: (2023-09-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
حسب: Larisa A. Dobrynina, وآخرون
منشور في: (2023-06-01)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
حسب: Christopher Kjaer Cullum, وآخرون
منشور في: (2023-08-01)

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
حسب: Piero Barbanti, وآخرون
منشور في: (2024-03-01)

Fremanezumab in real-life clinical practice: specialized headache center experience
حسب: Yu. E. Azimova, وآخرون
منشور في: (2024-06-01)

Current concept of the pathophysiology of migraine and new targets for its therapy
حسب: G. R. Tabeeva, وآخرون
منشور في: (2020-08-01)

Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study
حسب: Ji-Hoon Na, وآخرون
منشور في: (2025-05-01)

Migraine and cluster headache – the common link
حسب: Anne Luise Vollesen, وآخرون
منشور في: (2018-09-01)

Semi-Automated Recording of Facial Sensitivity in Rat Demonstrates Antinociceptive Effects of the Anti-CGRP Antibody Fremanezumab
حسب: Nicola Benedicter, وآخرون
منشور في: (2023-04-01)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
حسب: Theodoros Mavridis, وآخرون
منشور في: (2021-07-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
حسب: Magdalena Nowaczewska, وآخرون
منشور في: (2022-05-01)

Use of rimegepant as an alternative to triptans in migraine treatment
حسب: Aleksandra Jaroń, وآخرون
منشور في: (2024-08-01)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
حسب: Min Hou, وآخرون
منشور في: (2017-04-01)

Hallmarks of primary headache: part 1 – migraine
حسب: Alberto Raggi, وآخرون
منشور في: (2024-10-01)

Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review
حسب: Patricia Pozo-Rosich, وآخرون
منشور في: (2024-11-01)

Efficacy and continuability of 675 mg fremanezumab administration over 2 years
حسب: Shohei Yoshida, وآخرون
منشور في: (2025-03-01)

Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries
حسب: Lena Ohlsson, وآخرون
منشور في: (2018-08-01)

CGRP: New Focus in Migraine
حسب: Necdet Karlı, وآخرون
منشور في: (2022-03-01)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
حسب: Pınar Yalinay Dikmen, وآخرون
منشور في: (2023-11-01)

Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
حسب: Mamoru Shibata, وآخرون
منشور في: (2024-01-01)

Comparison of Early-onset Efficacy of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies for Patients with Migraine in Real-world Clinical Practice: Study Protocol for an Exploratory Clinical Trial
حسب: Takafumi TANEI, وآخرون
منشور في: (2025-02-01)